Martin Unverdorben

Martin Unverdorben


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

3 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina
YKYoung-Hoon Kim
Young-Hoon Kim
YKYukihiro Koretsune
Yukihiro Koretsune
CWChun-Chieh Wang
Chun-Chieh Wang
TYTakeshi Yamashita
Takeshi Yamashita
PKPaulus Kirchhof
Paulus Kirchhof
Non-vitamin K antagonist oral anticoagulants such as edoxaban are the standard of care for stroke prevention in patients with atrial fibrillation (AF). The Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program integrates prospective, observational, noninterventional regional studies from Europe, Japan, and other Asian countries, collecting data on patient characteristics and clinical outcomes in unselected patients treated with edoxaban for stroke prevention in AF. Overall, 26,823 patients completed a 1-year follow-up and were treated with edoxaban; either 60 or 30 mg once daily. The majority (82.6%) of patients received the recommended doses according to the local label. At baseline, the median (interquartile range) age was 75 (68, 80) years, the CHA2DS2-VASc score was 3.0 (2.0, 4.0), and the hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs, or alcohol (HAS-BLED) score was 2.0 (2.0, 3.0). At one year, there were 273 (1.12%/year) major bleeding events, including 75 (0.31%/year) intracranial hemorrhages and 140 (0.57%/year) major gastrointestinal (GI) bleeds. There were 214 ischemic strokes (0.87%/year). Mortality was 3.03%/year (745 deaths), and cardiovascular mortality accounted for 40% of all deaths (1.22%/year, 299 cardiovascular deaths). In conclusion, stroke, intracranial hemorrhage, and other major bleeding events were low in patients with AF treated with edoxaban in routine care. Even on anticoagulation, cardiovascular death remained common.

27 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TCTze-Fan Chao
Tze-Fan Chao
MUMartin Unverdorben
Martin Unverdorben
PKPaulus Kirchhof
Paulus Kirchhof
YKYukihiro Koretsune
Yukihiro Koretsune
TYTakeshi Yamashita
Takeshi Yamashita
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina
Non-recommended dosing occurs in ~25–50% of non-vitamin K antagonist oral anticoagulant prescriptions, with limited data for edoxaban. We analyzed edoxaban dosing patterns in atrial fibrillation patients from the Global ETNA-AF program, relating patterns to baseline characteristics and 1-year clinical outcomes. The following dosing groups were compared: non-recommended 60 mg (“overdosed”) vs. recommended 30 mg; non-recommended 30 mg (“underdosed”) vs. recommended 60 mg. Most (22,166/26,823; 82.6%) patients received recommended doses. Non-recommended dosing was more frequent near label-specified dose-reduction thresholds. Ischemic stroke (IS; HR 0.85, 95% CI 0.50–1.47; p = 0.6) and major bleeding (MB; HR 1.47, 95% CI 0.97–2.71; p = 0.07) did not differ between recommended 60 mg and “underdosed” groups, whereas all-cause (HR 1.61, 95% CI 1.23–2.08; p = 0.0003) and cardiovascular deaths (HR 1.61, 95% CI 1.11–2.38; p = 0.01) were higher in the “underdosed” group. Compared with recommended 30 mg, the “overdosed” group had lower IS (HR 0.51, 95% CI 0.28–0.98; p = 0.04) and all-cause death (HR 0.74, 95% CI 0.55–0.98; p = 0.03) without higher MB (HR 0.74, 95% CI 0.46–1.22; p = 0.2). In conclusion: non-recommended dosing was infrequent, but more common near dose-reduction thresholds. “Underdosing” was not associated with better clinical outcomes. The “overdosed” group had lower IS and all-cause death without higher MB.

16 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ECEue-Keun Choi
Eue-Keun Choi
WLWei-Shiang Lin
Wei-Shiang Lin
GHGyo-Seung Hwang
Gyo-Seung Hwang
PKPaulus Kirchhof
Paulus Kirchhof
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina
YKYoung-Hoon Kim
Young-Hoon Kim
Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from routine clinical practice, especially in Asian patients. Global ETNA (Edoxaban in rouTine cliNical prActice) is a noninterventional study that integrates data from patients from multiple regional registries into one database. Here, we report the 1-year clinical events from AF patients receiving edoxaban in South Korea and Taiwan. Clinical events assessed included bleeding, strokes, systemic embolic events, transient ischemic attacks (TIAs), and all-cause and cardiovascular death. Overall, 2677 patients (mean (range) age 72 (66–78) years, male 59.7%, mean CHA2DS2-VASc score ± standard deviation 3.1 ± 1.4) were treated with 60 or 30 mg edoxaban and had 1-year follow-up data. The annualized event rates for major bleeding and clinically relevant non-major (CRNM) bleeding were 0.78% and 0.47%, respectively. Annualized event rates for ischemic stroke and hemorrhagic stroke were 0.90% and 0.19%, respectively. Event rates for major and CRNM bleeding and rates of ischemic stroke and TIA were higher in Taiwanese patients than in Korean patients. Event rates were low and similar to those found in other studies of edoxaban in Korean and Taiwanese AF patients, thus supporting the safety and effectiveness of edoxaban in this population.

1 December 2020 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MUMartin Unverdorben
Martin Unverdorben
CHChristian von Heymann
Christian von Heymann
Amparo SantamariaAmparo Santamaria
Amparo Santamaria
MSM. Saxena
M. Saxena
TVT. Vanassche
T. Vanassche
PCP. Colonna
P. Colonna
Background: Annually > 10% of patients with atrial fibrillation on oral anticoagulation undergo invasive procedures. Optimal peri-procedural management of anticoagulation, as judged by major bleeding and thromboembolic events, especially in the elderly, is still debated. Methods: Procedures from 1442 patients were evaluated. Peri-procedural edoxaban management was guided only by the experience of the attending physician. The primary safety outcome was the rate of major bleeding. Secondary outcomes included the peri-procedural administration of edoxaban, other bleeding events, and the main efficacy outcome, a composite of acute coronary syndrome, non-hemorrhagic stroke, transient ischemic attack, systemic embolic events, deep vein thrombosis, pulmonary embolism, and mortality. Results: Of the 1442 patients, 280 (19%) were < 65, 550 (38%) were 65–74, 514 (36%) 75–84, and 98 (7%) were 85 years old or older. With increasing age, comorbidities and risk scores were higher. Any bleeding complications were uncommon across all ages, ranging from 3.9% in patients < 65 to 4.1% in those 85 years or older; major bleeding rates in any age group were ≤ 0.6%. Interruption rates and duration increased with advancing age. Thromboembolic events were more common in the elderly, with all nine events occurring in those > 65, and seven in patients aged > 75 years. Conclusion: Despite increased bleeding risk factors in the elderly, bleeding rates were small and similar across all age groups. However, there was a trend toward more thromboembolic complications with advancing age. Further efforts to identify the optimal management to reduce ischemic complications are needed. Trial registration: NCT# 02950168, October 31, 2016

21 January 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
RSRobert Semco
Robert Semco
RBRegan W. Bergmark
Regan W. Bergmark
SMSabina A. Murphy
Sabina A. Murphy
ACAbby L. Cange
Abby L. Cange
MUMartin Unverdorben
Martin Unverdorben
BBBrian A. Bergmark
Brian A. Bergmark
Background: Epistaxis is common with antithrombotic therapy and is often troublesome to patients, yet its frequency, severity, and outcomes are poorly characterized. Methods and Results: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF‐TIMI 48) randomized 21 105 patients with atrial fibrillation and CHADS2 risk score ≥2 to higher‐dose edoxaban regimen (60 mg daily, dose‐reduced to 30 mg), lower‐dose edoxaban regimen (30 mg, dose reduced to 15 mg, daily), or warfarin. Bleeds were adjudicated using International Society on Thrombosis and Haemostasis criteria. Patients with intracranial hemorrhage during follow‐up were excluded; those with >1 bleeding event were categorized according to their most severe event. The safety cohort with interval censoring during drug interruption was analyzed. Proportions were compared using Pearson's chi‐square test and treatment arms were compared using a Cox proportional hazards model. Among 5247 patients with a bleeding event, 1008 (19.2%) had epistaxis and 4239 (80.8%) had nonepistaxis bleeding. Epistaxis events were less severe than nonepistaxis bleeds (International Society on Thrombosis and Haemostasis major: 3.2% versus 20.7%; clinically relevant nonmajor: 64.7% versus 60.1%; minor: 32.1% versus 19.2%; P <0.001). Permanent drug discontinuation was similar following epistaxis versus nonepistaxis bleeding in patients with major (59.4% versus 53.6%; P =0.52) or clinically relevant nonmajor (32.5% versus 33.3%; P =0.70) bleeding but was significantly higher in patients with minor epistaxis versus other minor bleeds (33.3% versus 23.9%; P =0.001). Compared with warfarin, higher‐dose edoxaban regimen had similar risk of epistaxis (hazard ratio [HR], 1.09 [95% CI, 0.95–1.26]), whereas lower‐dose edoxaban regimen conferred reduced risk (HR, 0.73 [95% CI, 0.62–0.86]). Conclusions: Epistaxis was frequent, and despite being overall less severe than nonepistaxis bleeding, was associated with similar rates of anticoagulant discontinuation. Compared with warfarin, lower‐dose edoxaban regimen reduced the risk of epistaxis by 27% whereas higher‐dose edoxaban regimen had no effect. Registration: URL: https://clinicaltrials.gov ; Unique Identifier: NCT00781391 .